[go: up one dir, main page]

PL3013366T3 - Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1 - Google Patents

Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1

Info

Publication number
PL3013366T3
PL3013366T3 PL14739078T PL14739078T PL3013366T3 PL 3013366 T3 PL3013366 T3 PL 3013366T3 PL 14739078 T PL14739078 T PL 14739078T PL 14739078 T PL14739078 T PL 14739078T PL 3013366 T3 PL3013366 T3 PL 3013366T3
Authority
PL
Poland
Prior art keywords
inhibitor
combination therapy
factor xii
factor
xii inhibitor
Prior art date
Application number
PL14739078T
Other languages
English (en)
Inventor
Marc Nolte
Ingo Pragst
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL3013366T3 publication Critical patent/PL3013366T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
PL14739078T 2013-06-28 2014-06-27 Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1 PL3013366T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361840662P 2013-06-28 2013-06-28
EP13176605 2013-07-16
EP14739078.5A EP3013366B1 (en) 2013-06-28 2014-06-27 Combination therapy using a factor xii inhibitor and a c1-inhibitor
PCT/EP2014/063691 WO2014207199A1 (en) 2013-06-28 2014-06-27 Combination therapy using a factor xii inhibitor and a c1-inhibitor

Publications (1)

Publication Number Publication Date
PL3013366T3 true PL3013366T3 (pl) 2022-01-17

Family

ID=48793048

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14739078T PL3013366T3 (pl) 2013-06-28 2014-06-27 Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1

Country Status (10)

Country Link
US (3) US20160166660A1 (pl)
EP (1) EP3013366B1 (pl)
JP (1) JP2017501968A (pl)
KR (1) KR20160026905A (pl)
CN (1) CN105339010A (pl)
AU (1) AU2014301041B2 (pl)
CA (1) CA2916399C (pl)
ES (1) ES2897746T3 (pl)
PL (1) PL3013366T3 (pl)
WO (1) WO2014207199A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954052B1 (ko) 2011-03-09 2019-03-06 체에스엘 베링 게엠베하 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 xii 억제제
EP2964255B1 (en) 2013-03-08 2020-11-04 CSL Behring GmbH Treatment and prevention of remote ischemia-reperfusion injury
BR112016010837A8 (pt) 2013-11-13 2020-04-22 Shire Viropharma Inc uso de uma composição compreendendo um inibidor de c1-esterase (c1-inh), composição farmacêutica compreendendo o mesmo e seus kits
KR102513050B1 (ko) * 2014-06-18 2023-03-29 체에스엘 베링 게엠베하 신경외상성 장애에서의 인자 xii 억제제를 이용한 치료요법
EA201791527A1 (ru) 2015-01-02 2017-12-29 Дайэкс Корп. Биспецифические антитела против плазменного калликреина и фактора xii
EP4011916A1 (en) 2015-07-21 2022-06-15 Takeda Pharmaceutical Company Limited A monoclonal antibody inhibitor of factor xiia
WO2017027771A1 (en) 2015-08-13 2017-02-16 Dyax Corp. Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
WO2017173494A1 (en) * 2016-04-06 2017-10-12 Csl Limited Method of treating atherosclerosis
WO2018024873A1 (en) 2016-08-05 2018-02-08 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
AU2017316513A1 (en) * 2016-08-23 2019-03-28 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
WO2019113642A1 (en) * 2017-12-15 2019-06-20 Csl Limited Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
JP7152072B2 (ja) 2018-07-31 2022-10-12 レモネックス インコーポレイテッド Ctgf発現抑制用組成物
JP7709970B2 (ja) * 2019-12-03 2025-07-17 シーエスエル・イノベーション・プロプライエタリー・リミテッド 遺伝性血管性浮腫の治療または予防のための抗第xii因子抗体の使用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3228502A1 (de) 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
EP0534988A1 (en) 1990-05-10 1993-04-07 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
DE4222534A1 (de) 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE4244735A1 (de) 1992-08-24 1994-03-31 Behringwerke Ag Verwendung von C1-Inaktivator zur Bekämpfung von Komplikationen bei der Anwendung von Zytokinen, endogenen Mediatoren, gentechnisch produzierten Mediator-Hybriden oder Wachstumsfaktoren im Rahmen der therapeutischen Anwendung dieser Substanzen
DE69429816T2 (de) * 1993-09-01 2002-09-19 Stichting Sanquin Bloedvoorziening, Amsterdam C1-Esterasehemmer zur Verringerung von Myokardschäden bei akutem Herzinfarkt
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
DE19903693A1 (de) * 1998-04-24 1999-10-28 Centeon Pharma Gmbh Protease zur Aktivierung des Gerinnungsfaktors VII
JPH11209399A (ja) * 1997-11-20 1999-08-03 Asahi Chem Ind Co Ltd 高比重リポ蛋白質を有効成分とする医薬組成物
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
GB9800817D0 (en) * 1998-01-16 1998-03-11 Bio Discovery Ltd Serine protease inhibitors
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001019392A1 (en) 1999-09-16 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
AU2001274809A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK2298347T3 (en) 2003-05-06 2016-01-11 Biogen Hemophilia Inc COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
BRPI0411132B8 (pt) 2003-06-12 2021-05-25 Lilly Co Eli protéina de fusão heteróloga e seus usos
AU2004271200A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Fc-에리스로포이에틴 융합단백질
ES2407965T3 (es) 2004-12-23 2013-06-17 Csl Behring Gmbh Prevención de la formación y/o estabilización de trombos
KR101508668B1 (ko) * 2005-12-21 2015-04-06 파밍 인텔렉츄얼 프라퍼티 비.브이. 허혈-재관류 손상의 예방을 위한 c1 억제제의 용도
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
US20100119512A1 (en) * 2007-01-25 2010-05-13 Joslin Diabetes Center Methods of diagnosing, treating, and preventing increased vascular permeability
CA2678001C (en) * 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
RU2660370C2 (ru) * 2011-07-22 2018-07-05 Цсл Беринг Гмбх Ингибирующие моноклональные антитела против фактора xii/xiia и их применения

Also Published As

Publication number Publication date
CA2916399A1 (en) 2014-12-31
HK1220132A1 (zh) 2017-04-28
EP3013366B1 (en) 2021-08-25
US20200129600A1 (en) 2020-04-30
WO2014207199A1 (en) 2014-12-31
KR20160026905A (ko) 2016-03-09
EP3013366A1 (en) 2016-05-04
AU2014301041B2 (en) 2019-10-31
US20160166660A1 (en) 2016-06-16
AU2014301041A1 (en) 2016-01-21
CN105339010A (zh) 2016-02-17
ES2897746T3 (es) 2022-03-02
CA2916399C (en) 2022-08-02
US20240398914A1 (en) 2024-12-05
JP2017501968A (ja) 2017-01-19

Similar Documents

Publication Publication Date Title
IL272921A (en) Combined treatment including a B-Raf inhibitor and a second inhibitor
PL3013366T3 (pl) Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
IL256946B (en) Bromodomain inhibitors
IL243372A0 (en) bromine zone inhibitors
HUE070659T2 (hu) KDM1A inhibitor és annak felhasználása terápiában
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
EP2989549A4 (en) CONTROLLING THE INTEGRITY OF A REFERENCE COUNTER
GB201413104D0 (en) Use of ancillary devices in radiotherapy systems
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
EP3041028A4 (en) LAMINATE AND ITS APPLICATION
GB201307269D0 (en) Combination Therapy
GB201307899D0 (en) A laminate structure
GB201306772D0 (en) A memorial for use in a place of rememberance
DK3013366T3 (da) Kombinationsterapi under anvendelse af en faktor xii-inhibitor og en c1-inhibitor
SG11201507720PA (en) Anti-tumoral composition comprising a pi3kbeta-selective inhibitor and a pi3kalpha-selective inhibitor
HK1232804A1 (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
GB201317994D0 (en) A Portable Lounger
GB201317661D0 (en) Resuscitation
GB201316081D0 (en) A portable barrier
GB201305503D0 (en) Inhibitor